請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65421完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊長豪(Chang-Hao Yang) | |
| dc.contributor.author | Yi-An Lee | en |
| dc.contributor.author | 李毅安 | zh_TW |
| dc.date.accessioned | 2021-06-16T23:41:54Z | - |
| dc.date.available | 2012-09-19 | |
| dc.date.copyright | 2012-09-19 | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012-07-25 | |
| dc.identifier.citation | Allen JB, Keng T, Privalle C. Nitric oxide and peroxynitrite production in ocular inflammation. Environ Health Perspect. 1998 Oct;106 Suppl 5:1145-9.
An J, Sun Y, Fisher M, Rettig MB. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther. 2004 Jun;3(6):727-36. Anderson NG, Garcia-Valenzuela E, Martin DF. Hypopyon uveitis and relapsing polychondritis: a report of 2 patients and review of autoimmune hypopyon uveitis. Ophthalmology. 2004 Jun;111(6):1251-4. Andriantsitohaina R, Duluc L, García-Rodríguez JC, Gil-del Valle L, Guevara-Garcia M, Simard G, Soleti R, Su DF, Velásquez-Pérez L, Wilson JX, Laher I. Systems biology of antioxidants. Clin Sci (Lond). 2012 Aug 1;123(3):173-92. Becker MD, Dullforce PA, Martin TM, Smith JR, Planck SR, Rosenbaum JT. Immune mechanisms in uveitis. What can be learned from in vivo imaging? Ophthalmol Clin North Am. 2002 Sep;15(3):259-70. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol. 1997 Jul-Aug;42(1):71-82. Bodaghi B, LeHoang P. Testing ocular fluids in uveitis. Ophthalmol Clin North Am. 2002 Sep;15(3):271-9. Bodaghi B. Viral uveitis. J Fr Ophtalmol. 2004 May;27(5):528-37. Bora NS, Kaplan HJ. Intraocular diseases - anterior uveitis. Chem Immunol Allergy. 2007;92:213-20. Brézin AP, Monnet D, Cohen JH, Levinson RD. HLA-A29 and birdshot chorioretinopathy. Ocul Immunol Inflamm. 2011 Dec;19(6):397-400. Bryk R, Wolff DJ. Pharmacological modulation of nitric oxide synthesis by mechanism-based inactivators and related inhibitors. Pharmacol Ther. 1999 Nov;84(2):157-78. Calamia KT. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adv Exp Med Biol. 2003;528:545-9. Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010 Sep;120(9):3073-83. doi: 10.1172/JCI42440. Chang YH, Horng CT, Chen YH, Chen PL, Chen CL, Liang CM, Chien MW, Chen JT. Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5441-9. Commodaro AG, Bueno V, Belfort R Jr, Rizzo LV. Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation. Autoimmun Rev. 2011 Feb;10(4):205-9. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003 May;2(3):119-25. Crane IJ, Forrester JV. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol. 2005;25(2):75-102. Damico FM, Bezerra FT, Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009 May-Jun;72(3):413-20. Dunn JP. Review of immunosuppressive drug therapy in uveitis. Curr Opin Ophthalmol. 2004 Aug;15(4):293-8. Egea J, García AG, Verges J, Montell E, López MG. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S24-7. Espinosa G, Cervera R, Reverter JC, Tàssies D, Font J, Ingelmo M. Vascular involvement in Behçet's disease. Isr Med Assoc J. 2002 Aug;4(8):614-6. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol. 2005 Jul;56(1):46-54. Fang IM, Yang CH, Lin CP, Yang CM, Chen MS. Effects of pyrrolidine dithiocarbamate, an NF-kappaB inhibitor, on cytokine expression and ocular inflammation in experimental autoimmune anterior uveitis. J Ocul Pharmacol Ther. 2005 Apr;21(2):95-106. Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 2008 Feb 21;27(9):1189-97. Forrester JV, Xu H, Kuffová L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. Immunol Rev. 2010 Mar;234(1):282-304. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol. 2008 Nov;8(11):837-48. Giuliari GP, Hinkle DM, Foster CS. Local treatment for lymphoid malignancies of the eye. Anticancer Agents Med Chem. 2009 Dec;9(10):1123-8. Habermeier A, Wolf S, Martiné U, Gräf P, Closs EI. Two amino acid residues determine the low substrate affinity of human cationic amino acid transporter-2A. J Biol Chem. 2003 May 23;278(21):19492-9. Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist's office: are a patient's eye symptoms serious? Cleve Clin J Med. 2005 Apr;72(4):329-39. Hammermann R, Dreissig MD, Mössner J, Fuhrmann M, Berrino L, Göthert M, Racké K. Nuclear factor-kappaB mediates simultaneous induction of inducible nitric-oxide synthase and Up-regulation of the cationic amino acid transporter CAT-2B in rat alveolar macrophages. Mol Pharmacol. 2000 Dec;58(6):1294-302. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011 Oct;31(10):733-44. Islam N, Pavesio C. Uveitis (acute anterior). Clin Evid (Online). 2010 Apr 8;2010. pii: 0705. Jaeger K, Paulsen F, Wohlrab J. Characterization of cationic amino acid transporters (hCATs) 1 and 2 in human skin. Histochem Cell Biol. 2008 Mar;129(3):321-9. Jäger K, Bönisch U, Risch M, Worlitzsch D, Paulsen F. Detection and regulation of cationic amino acid transporters in healthy and diseased ocular surface. Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1112-21. Kagemann G, Sies H, Schnorr O. Limited availability of L-arginine increases DNA-binding activity of NF-kappaB and contributes to regulation of iNOS expression. J Mol Med (Berl). 2007 Jul;85(7):723-32. Kansu T, Kadayifcilar S. Visual aspects of Behçet's disease. Curr Neurol Neurosci Rep. 2005 Sep;5(5):382-8. Keino H. Therapeutic effect of the low molecular weight inhibitor of the NF-kappaB signaling pathway on experimental autoimmune uveoretinitis. Nihon Ganka Gakkai Zasshi. 2010 Nov;114(11):944-54. Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res. 2010 Nov;29(6):610-21. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother. 2009 Oct;10(15):2511-25. Kirsch O, Lautier-Frau M, Labetoulle M, Offret H, Frau E. Characteristics of uveitis presenting de novo in the elderly. J Fr Ophtalmol. 2003 Sep;26(7):720-4. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003 Nov;56(3):307-18. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011 Jun;16(2):309-22. Levinson RD, Gonzales CR. Birdshot retinochoroidopathy: immunopathogenesis, evaluation, and treatment. Ophthalmol Clin North Am. 2002 Sep;15(3):343-50, vii. Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, Vera Recabarren M, Espinosa G, Jara Quezada J, Cervera R. Etiopathogenesis of Behcet's disease. Autoimmun Rev. 2010 Feb;9(4):241-5. Menezo V, Lightman S. The eye in systemic vasculitis. Clin Med. 2004 May-Jun;4(3):250-4. Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Secondary glaucoma in patients with uveitis. Ophthalmologica. 1999;213(5):300-4. Mochizuki M. Regional immunity of the eye. Acta Ophthalmol. 2010 May;88(3):292-9. Epub 2009 Nov 7. Montañez R, Rodríguez-Caso C, Sánchez-Jiménez F, Medina MA. In silico analysis of arginine catabolism as a source of nitric oxide or polyamines in endothelial cells. Amino Acids. 2008 Feb;34(2):223-9. Mota LA, Santos AB. Vogt-Koyanagi-Harada's syndrome and its multisystem involvement. Rev Assoc Med Bras. 2010 Sep-Oct;56(5):590-5. Niese KA, Chiaramonte MG, Ellies LG, Rothenberg ME, Zimmermann N. The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis. Respir Res. 2010 Jun 24;11:87. Pato E, Muñoz-Fernández S, Francisco F, Abad MA, Maese J, Ortiz A, Carmona L; Uveitis Working Group from Spanish Society of Rheumatology. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011 Feb;40(4):314-23. Pras E, Neumann R, Zandman-Goddard G, Levy Y, Assia EI, Shoenfeld Y, Langevitz P. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum. 2004 Dec;34(3):602-9. Read RW. Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am. 2002 Sep;15(3):333-41, vii. Rothenberg ME, Doepker MP, Lewkowich IP, Chiaramonte MG, Stringer KF, Finkelman FD, MacLeod CL, Ellies LG, Zimmermann N. Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14895-900. Sancak B, Onder M, Oztas MO, Bukan N, Gürer MA. Nitric oxide levels in Behçet's disease. J Eur Acad Dermatol Venereol. 2003 Jan;17(1):7-9. Schnorr O, Suschek CV, Kolb-Bachofen V. The importance of cationic amino acid transporter expression in human skin. J Invest Dermatol. 2003 Jun;120(6):1016-22. Schwartz D, Schwartz IF, Gnessin E, Wollman Y, Chernichovsky T, Blum M, Iaina A. Differential regulation of glomerular arginine transporters (CAT-1 and CAT-2) in lipopolysaccharide-treated rats. Am J Physiol Renal Physiol. 2003 Apr;284(4):F788-95. Schwartz IF, Hershkovitz R, Iaina A, Gnessin E, Wollman Y, Chernichowski T, Blum M, Levo Y, Schwartz D. Garlic attenuates nitric oxide production in rat cardiac myocytes through inhibition of inducible nitric oxide synthase and the arginine transporter CAT-2 (cationic amino acid transporter-2). Clin Sci (Lond). 2002 May;102(5):487-93. Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Expert Opin Biol Ther. 2012 Mar;12(3):311-28. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10771-8. Shindo Y, Ohno S. Eye involvement of autoimmune disease. Arerugi. 2003 Jun;52(6):518-21. Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010 Aug;9(10):674-83. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol. 1998 Dec;76(6):497-512. Srivastava A, Rajappa M, Kaur J. Uveitis: Mechanisms and recent advances in therapy. Clin Chim Acta. 2010 Sep 6;411(17-18):1165-71. Takeuchi M. Immune tolerance and autoimmune uveoretinitis: the role of the ocular microenvironment. Immunotherapy. 2011 Sep;3(9):1103-11. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 Suppl 1:46-53. Thadani SM, Foster CS. Treatment of ocular inflammation in children. Paediatr Drugs. 2004;6(5):289-301. Thompson RW, Pesce JT, Ramalingam T, Wilson MS, White S, Cheever AW, Ricklefs SM, Porcella SF, Li L, Ellies LG, Wynn TA. Cationic amino acid transporter-2 regulates immunity by modulating arginase activity. PLoS Pathog. 2008 Mar 14;4(3):e1000023. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004 Feb;447(5):532-42. Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, Wildner G, Dick AD. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res. 2012 Mar;31(2):182-94. Yang CH, Tsai PS, Lee JJ, Huang CH, Huang CJ. NF-kappaB inhibitors stabilize the mRNA of high-affinity type-2 cationic amino acid transporter in LPS-stimulated rat liver. Acta Anaesthesiol Scand. 2005 Apr;49(4):468-76. Yang S, Huang CJ, Tsai PS, Cheng CR, Stevens BR, Skimming JW. Renal transcription of high-affinity type-2 cationic amino acid transporter is up-regulated in LPS-stimulated rodents. Acta Anaesthesiol Scand. 2004 Mar;48(3):308-16. Yeramian A, Martin L, Arpa L, Bertran J, Soler C, McLeod C, Modolell M, Palacín M, Lloberas J, Celada A. Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol. 2006 Jun;36(6):1516-26. Yeramian A, Martin L, Serrat N, Arpa L, Soler C, Bertran J, McLeod C, Palacín M, Modolell M, Lloberas J, Celada A. Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J Immunol. 2006 May 15;176(10):5918-24. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65421 | - |
| dc.description.abstract | 研究目的：研究cationic amino acid transporter和inducible nitric oxide synthase在endotoxin-induced uveitis中的表現。
研究方法：endotoxin-induced uveitis主要是將200 μg的lipopolysaccharide注射到Lewis rats的footpad中來誘導出uveitis。我們使用bortezomib (velcade)在注射lipopolysaccharide 30分鐘前進行腹腔內注射，作為proteasome inhibitor來研究nuclear factor-kappa B被抑制時的情形。Lewis rats在注射lipopolysaccharide 24 小時後被犧牲，並將其眼部組織取出研究。我們以RT-PCR和Western blotting研究inducible nitric oxide synthase以及cationic amino acid transporter之蛋白還有他們的mRNA在iris-ciliary body的表現；此外，我們利用ELISA 來測定aqueous中nitric oxide的量。另一方面，我們將iris及ciliary的組織切片進行 immunochemical staining來研究inducible nitric oxide synthase以及cationic amino acid transporter的表現，並研究velcade對它們的抑制效果。關於nuclear factor-kappa B的活性則是透過electrophoretic mobility shift assay來測定。除了動物模式之外，我們還利用RAW 264.7 cell這樣的細胞研究模式來驗證我們的理論。 結果：Lewis rats在注射velcade之後，在組織切片所觀察到的inflammation程度下降，aqueous中NO的production也減少。我們的研究結果也顯示出inducible nitric oxide synthase以及cationic amino acid transporter-2的表現量及其mRNA的表現量都有受到velcade的抑制。透過electrophoretic mobility shift assay也證實了nuclear factor-kappa B的活性受到velcade的抑制。另一方面，在RAW 264.7 cell的研究上也得到同樣的結果。 結論：我們證實了cationic amino acid transporter在眼內組織的存在，也發現nuclear factor-kappa B對於inducible nitric oxide synthase以及cationic amino acid transporter-2的表現都有促進的效果。而nuclear factor-kappa B、inducible nitric oxide synthase、cationic amino acid transporter-2以及nitric oxide都是葡萄膜炎的發炎反應中不可或缺的重要因子。 | zh_TW |
| dc.description.abstract | Purpose：To examine the expression of cationic amino acid transporter (CAT) and inducible nitric oxide synthase (iNOS) in endotoxin-induced uveitis (EIU).
Methods：EIU was induced by a footpad injection of 200 μg LPS in Lewis rats. Proteasome inhibitor bortezomib (valcade) was injected intraperitoneally 30 minutes before the LPS administration. The rats were sacrificed 24 hours later and the eyes were enucleated. The expression of iNOS and CAT mRNA and protein in the iris and ciliary body was determined by RT-PCR and Western blotting. The production of NO in aqueous was measured by ELISA. Immunochemical staining of the iris and ciliary body was performed to evaluate the inhibitory effect of valcade. The activity of NF-κB was assessed by electrophoretic mobility shift assay (EMSA). In addition to animal model, we also used RAW264.7 cells as an animal model to investigate our hypothesis. Results： Proteasome inhibitor valcade abrogated the inflammation of EIU as demonstrated by immunochemical stain and the decreased NO production in aqueous. The expression of iNOS and CAT mRNA in EIU mouse eyes were suppressed by valcade. Supershift assay revealed that NF-κB activation was responsible for iNOS and CAT induction. Similar results were found in cellular model study. Conclusions：We confirmed the existence of CAT in intraocular tissue. NF-κB is an essential transcription factor not only for the induction of iNOS, but also for the up-regulation of CAT-2. The simultaneous up-regulation of CAT-2 and iNOS may play an important role in the pathogenesis of EIU. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T23:41:54Z (GMT). No. of bitstreams: 1 ntu-101-P99421019-1.pdf: 1829311 bytes, checksum: a2c2541cc0c6761af3349e727064821d (MD5) Previous issue date: 2012 | en |
| dc.description.tableofcontents | 目 錄
口試委員會審定書………………………………………………………………… i 誌謝………………………………………………………………………………… ii 中文摘要………………………………………………………………………… iii 英文摘要…………………………………………………………………………. iv 目錄 ………………………………………………………………………………. v 一、 緒論 …………………………………………………………………………1 二、 研究方法與材料……………………………………………………………..6 三、 結果 …………………………………………………………………………11 四、 討論 …………………………………………………………………………16 五、 展望 …………………………………………………………………………23 六、 參考文獻 …………………………………………………………………...26 七、 圖表 …………………………………………………………………………36 | |
| dc.language.iso | zh-TW | |
| dc.title | Inducible Nitric Oxide Synthase和Cationic Amino Acid Transporter在Endotoxin-Induced Uveitis的表現 | zh_TW |
| dc.title | Expression of Inducible Nitric Oxide Synthase and Cationic Amino Acid Transporter in Endotoxin-Induced Uveitis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊中美(Chung-May Yang),楊偉勛(Wei-Shiung Yang) | |
| dc.subject.keyword | 葡萄膜炎,誘導一氧化氮合成酶,陽性氨基酸傳遞子-1,陽性氨基酸傳遞子-2,一氧化氮, | zh_TW |
| dc.subject.keyword | uveitis,inducible nitric oxide synthase,cationic amino acid transporter-1,cationic amino acid transporter-2,nitric oxide, | en |
| dc.relation.page | 47 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-07-25 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-101-1.pdf 目前未授權公開取用 | 1.79 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。